Back to Market返回行情

HURA TuHURA Biosciences, Inc.

USHealthcare
$2.39+2.14%ClosedMarket Cap: $152.2M

As of 2026-07-10 16:00

Why HURA matters now

TuHURA Biosciences, Inc. (HURA) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.39 with +2.14% on the session and $152.2M in market capitalization; recent performance reads 1-month +4.47% and YTD +239.63%.

The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-7.5M, and EPS of $-0.13. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -16.7%.

The latest indexable market news headline is "TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers" from PRNewsWire.

Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Bianco James A. filing G-Gift. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

6.65

P/S

0.00

EV/EBITDA

-5.23

DCF Value

$-0.01

FCF Yield

-16.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-154.0%

ROA

-104.1%

ROIC

-135.5%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$0.00$-7.5M$-0.13
Q4 2025$0.00$-6.8M$-0.13
FY 2025$0.00$-30.1M$-0.63
Q3 2025$0.00$-7.1M$-0.14

Analyst Ratings

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

Strong Buy: 2Buy: 2Hold: 0Sell: 0Strong Sell: 0
HC Wainwright & Co.Buy
2026-02-03
Maxim GroupBuy
2025-11-14

Trading Activity

Insider Trades

Bianco James A.director, officer: Chief Executive Officer
Sell2026-05-29
Hoffman Robert E.director
Sell2026-02-17
List Alandirector
Sell2026-02-17
MANUSO JAMES S Jdirector
Sell2026-02-17
Ng George Kdirector
Sell2026-02-17

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

0.01

TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.